about
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.Atrial arrhythmogenicity of KCNJ2 mutations in short QT syndrome: Insights from virtual human atria.In silico investigation of a KCNQ1 mutation associated with short QT syndrome.Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine
P50
Q36085808-08598A7F-D478-4F56-8EA3-DEE3F65B552AQ36400524-34954B17-4255-4265-B160-C82FE59F5963Q41437149-E751BD59-2D8D-40F3-986D-AA52AF0500B3Q42021474-4A691408-D6CA-45E5-BAFD-22B8DFFD163FQ42173245-F572988E-42B9-4F3B-8CC3-6C40F31A5C4AQ42768918-DA53DA59-A197-4E05-B9F3-9CFE80732344Q53837170-935C7286-E4B0-4C15-A7F0-19702BFA71EFQ90142501-88ABC9DA-BB86-410A-B80B-2C899EC3DA17
P50
description
researcher
@en
wetenschapper
@nl
name
Aziza El Harchi
@en
Aziza El Harchi
@nl
type
label
Aziza El Harchi
@en
Aziza El Harchi
@nl
prefLabel
Aziza El Harchi
@en
Aziza El Harchi
@nl
P31
P496
0000-0003-3329-6234